KCM
MRVI icon

Kennedy Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Kennedy Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-66,125
Closed -$549K – 714
2024
Q3 		$549K Sell
66,125
-21,223
-24% -$183K 0.01% 632
2024
Q2 		$625K Sell
87,348
-9,929
-10% -$85.7K 0.01% 627
2024
Q1 		$843K Sell
97,277
-7,268
-7% -$49.2K 0.02% 631
2023
Q4 		$685K Sell
104,545
-164
-0.2% -$1.06K 0.02% 615
2023
Q3 		$1.05M Buy
+104,709
New +$1.15M 0.03% 559

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kennedy Capital Management's MRVI Position: Q4 2024 in Review

Kennedy Capital Management sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 66,125 shares — an estimated $549K sold.

Kennedy Capital Management first reported a position in MRVI in Q3 2023 and held it in 5 quarters. The position peaked at $1.05M in Q3 2023. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

  • Kennedy Capital Management reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 66,125 Maravai LifeSciences shares in Q4 2024, an estimated $549K.
  • Kennedy Capital Management first reported a position in Maravai LifeSciences in Q3 2023 and held it in 5 quarters.
  • Kennedy Capital Management's Maravai LifeSciences position peaked at $1.05M in Q3 2023.
  • 185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Kennedy Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.